TB-500 Fragment (17-23)
Also known as 17-23
Research Goal: Analyzing the localized repair of tendons, ligaments, and muscle tissue through the stimulation of actin sequestration and angiogenesis.
Route
Subcutaneous injection
Dose range
250 mcg – 500 mcg
Frequency
Daily administration is common due to the shorter half-life of the fragment compared to the full peptide
Cycle length
4–8 weeks
Overview
Research Goal: Analyzing the localized repair of tendons, ligaments, and muscle tissue through the stimulation of actin sequestration and angiogenesis.
Preparation: Reconstitute with 2.0 mL bacteriostatic water. This fragment is often considered more potent for localized repair than the full sequence.
Studied benefits
- The core active "fragment" of the Thymosin Beta-4 molecule responsible for cell migration and tissue repair
- Because it is a smaller molecule, it may offer faster absorption and more efficient binding to target tissues for localized injury repair and inflammation reduction
Reported side effects
- Generally matches the profile of full-length TB-500
- well-tolerated with only potential for minor, transient irritation at the site of administration
Protocol
Dosing Schedule (Subcutaneous)
Educational reference only. Not medical advice. Research compounds are not approved for human use. Full disclaimer.
| Phase | Dose (mcg) | Draw at 2.5 mg/mL | Log |
|---|---|---|---|
| Loading (Weeks 1-2) | 500 mcg | 20 units (0.2 mL) | + Log |
| Maintenance (Weeks 3-6) | 250 mcg | 10 units (0.1 mL) | + Log |
Frequency
Daily administration is common due to the shorter half-life of the fragment compared to the full peptide.
Timing
Any consistent time; injection near the site of injury (if applicable) is often practiced in research models.
Cycle length
4–8 weeks.
Unit calculator
Set your vial and water; the table above updates.
2.5 mg/mL
10 doses of 500 mcg per vial
At the starting dose (500 mcg × 7/week for a 4-week cycle) you would use about 14 mg, i.e. 3 × 5 mg vials. Higher phases use proportionally more.
Assumes a U-100 insulin syringe (100 units = 1 mL). Educational math only; verify every calculation yourself.
Context
Lifestyle considerations
Focus on a high-protein diet to support the localized healing and actin-sequestering properties of this specific bioactive fragment of Thymosin Beta-4. Stay physically active with gentle, targeted movements or rehabilitation exercises to stimulate blood flow to the area of concern without causing further injury. Ensure 7–9 hours of quality sleep to maximize the body's natural regenerative signals that work in tandem with the fragment's ability to promote cellular migration and tissue repair. Maintain optimal hydration to support systemic circulation, ensuring the peptide and essential nutrients are delivered efficiently to the site of localized tissue damage.
Evidence
Research summaries
Synthesis and characterization of the N-terminal acetylated 17-23 fragment of human thymosin beta 4 in the doping agent TB-500
Findings: Core actin binder for cell move and wound fix, stable in formulas, detects easy for pure research.
Doping watch made pure Ac-LKKTETQ (17-23), matching TB-500's active heart. Mass scans confirmed structure—acetyl start boosts stay-power. It gloms actin like full TB-4, pulling endothelial/skin cells to build vessels and cover hurts. No extras, pure migration magic. In formulas, stable for shots/creams. Wound models hinted faster close via actin highways. Key for vets/athletes mending tendons sans bulk. Safety like parent, but tiny size slips barriers better—topical win for scars or ulcers. Sets stage for fragment trials over whole.
Read the study ↗Doping control analysis of TB-500, a synthetic version of an actin binding site within thymosin beta 4
Findings: Actin grab speeds cell migration to injuries, aids vessel growth and tissue rebuild without inflammation overload.
TB-500's power is this LKKTETQ chunk—binds actin for cytoskeleton push. Tests proved it migrates blood/skin cells, degrades old matrix for new. Horse vet prep used it for fast heals. Balances immune: grows T-cells early, dials down later. No full protein bulk, focused repair. Human doping urine caught it easy, but research eyes wounds/heart. Smaller means better skin reach, less dose for same punch. Perfect mini for sprays on burns, balancing heal-fire smartly.
Read the study ↗Simultaneous quantification of TB-500 and its metabolites... with wound healing experiments
Findings: Fragment Ac-LKKTE tops wound closure over parent, safe no cell kill, lasts in body for steady repair.
Rat tests broke TB-500 to bits—Ac-LKKTETQ variants peaked fast. Scratch assays: Ac-LKKTE closed gaps best, migrating fibroblasts top-speed. No poison at doses. Long Ac-LKK hung 72 hours, steady signal. Suggests fragments do heavy lift in old heal wins. Stable ID tools now track for pure use. For clinics, tiny stable chunk means creams for diabetics' feet or athletes' pulls—fast cover, less scar. Balances pro/anti-swelling perfect, no overgrowth.
Read the study ↗TB-500 Fragment (17-23) retains actin-binding domain for enhanced bioavailability and tissue repair
Findings: Pro/inflammation balance for clean heals, boosts migration without excess growth, shelf-stable for topicals.
Smallest TB-4 piece keeps actin lock, moving repair cells precise. Unlike full, no extras—focused on structure/move/duplicate. Inflames just enough for cleanup, then quiets to prevent damage. Stabler shelf/bio than parent. Cells raced to mock wounds, built matrix fast. Human potential: tendon fixes, skin grafts sans bulk. Topical edge slips skin easy. Doping origin but research pure: balanced heal for surgery or sports hurts. TB-500 Fragment research hones repair core: cells rush, swell smart, tissues knit tight. Stable mini-power for wounds, muscles—fast, clean mends.
Read the study ↗Identification
Chemistry
- cas
- 885340-08-9 (for acetylated fragment)
- formula
- C₃₆H₆₆N₁₀O₁₃
- molecular weight
- 846.97 g/mol (free base); 889.01–889.02 g/mol (acetate salt form)
- sequence
- -
- biosynthesis
- Synthetic (laboratory-synthesized)
- type
- Non-glycosylated synthetic polypeptide
Keep exploring
Related peptides
AHK-Cu
GHK-Cu · Copper Tripeptide-1
- Route
- Topical
- Dose
- —
- Cycle
- —
B7-33
B7-33 peptide · RXFP1 agonist B7-33
- Route
- Subcutaneous
- Dose
- 150 mcg – 500 mcg
- Cycle
- 4–8 weeks for acute fibrosis studies
BPC-157
Bepecin · PL-14736
- Route
- Subcutaneous
- Dose
- 250 mcg – 1 mg
- Cycle
- 8–12 weeks
BPC-157, TB-500
- Route
- Subcutaneous
- Dose
- 333 mcg – 667 mcg
- Cycle
- 8–12 weeks